Page 31 - ஒன்றுபட்டது கிஂக்டம் தடுப்பூசி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant Company to host investor conference call today at 4:30pm ET GAITHERSBURG, Md., Jan. 28, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). The study assessed efficacy during a period with high transmission and with

United kingdomSouth africaSouth africansGregorym glennStanleyc erckClive dixInfectious diseases analytics research unitUs department of healthDepartment of defenseHuman servicesNational institutes of healthBiomedical advanced researchNational institute of allergyMelinda gates foundationDevelopment authorityCoalition for epidemic preparedness innovations